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Background: The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-
positive (ALKþ) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with
alectinib versus crizotinib. Here, we present detailed central nervous system (CNS) efficacy data from ALEX.
Patients and methods: Overall, 303 patients aged 18 years underwent 1:1 randomization to receive twice-daily doses of
alectinib 600mg or crizotinib 250mg. Brain imaging was conducted in all patients at baseline and every subsequent 8weeks.
End points (analyzed by subgroup: patients with/without baseline CNS metastases; patients with/without prior radiotherapy)
included PFS, CNS objective response rate (ORR), and time to CNS progression.
Results: In total, 122 patients had Independent Review Committee-assessed baseline CNS metastases (alectinib, n¼ 64; crizotinib,
n¼ 58), 43 hadmeasurable lesions (alectinib, n¼ 21; crizotinib, n¼ 22), and 46 had received prior radiotherapy (alectinib, n¼ 25;
crizotinib, n¼ 21). Investigator-assessed PFS with alectinib was consistent between patients with baseline CNSmetastases [hazard ratio
(HR) 0.40, 95% confidence interval (CI): 0.25–0.64] and those without (HR 0.51, 95% CI: 0.33–0.80, P interaction¼ 0.36). Similar results
were seen in patients regardless of prior radiotherapy. Time to CNS progression was significantly longer with alectinib versus crizotinib
and comparable between patients with and without baseline CNSmetastases (P< 0.0001). CNS ORR was 85.7% with alectinib versus
71.4% with crizotinib in patients who received prior radiotherapy and 78.6% versus 40.0%, respectively, in those who had not.
Conclusion: Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib
in patients with previously untreated, advanced ALKþ NSCLC, irrespective of prior CNS disease or radiotherapy.
Clinical trial registration: ClinicalTrials.gov NCT02075840
Key words: alectinib, ALK-positive, CNS, NSCLC
Introduction
Anaplastic lymphoma kinase-positive (ALKþ) non-small-cell
lung cancer (NSCLC) is characterized by a high prevalence of
central nervous system (CNS) involvement [1] and brain meta-
stases [2, 3]. Previously, crizotinib was the standard of care
(SOC) first-line treatment of ALKþNSCLC [4]. Most crizotinib-
treated patients relapse within 1 year because of poor CNS
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penetration [5] or development of resistance mutations [6]. In
the phase III PROFILE 1014 study, although intracranial disease
control rate was significantly higher with crizotinib than with
chemotherapy, there was no significant difference in intracranial
time to tumor progression between the treatments [7].
Alectinib is a highly selective ALK inhibitor with proven CNS
efficacy [8–13]. Unlike crizotinib, alectinib demonstrates effect-
ive CNS penetration and is not a substrate for P-glycoprotein,
which promotes efflux at the blood–brain barrier [11]. The
phase III ALEX trial (BO28984, NCT02075840) compared alec-
tinib with crizotinib as the first-line treatment for ALKþ
advanced NSCLC. Patients with/without asymptomatic CNS
metastases, including treated/untreated CNS disease, were per-
mitted. In the primary analysis, the primary end point
[investigator-assessed progression-free survival (PFS)] was sig-
nificantly improved with alectinib versus crizotinib: hazard
ratio (HR) 0.47 [95% confidence interval (CI): 0.34–0.65;
P< 0.001], median PFS for alectinib not reached (NR) [13].
With 10 months’ longer follow-up, median PFS was
34.8 months (95% CI: 17.7–not estimable) with alectinib and
10.9 months (95% CI: 9.1–12.9) with crizotinib (HR 0.43, 95%
CI: 0.32–0.58) [14]. Based on ALEX, alectinib was approved for
the first-line treatment of ALKþNSCLC.
ALEX was designed to capture CNS progression by prospect-
ively monitoring patients with uniform brain imaging. At the pri-
mary data analysis, 18 patients (12%) receiving alectinib had
CNS progression as the first progression event versus 68 patients
(45%) receiving crizotinib [cause-specific HR (csHR) 0.16; 95%
CI: 0.10–0.28; P< 0.001] [13]. Here, we report further CNS effi-
cacy results from ALEX.
Methods
Study design
Full methodology has been published [13]. Patients with stage III/IV
ALKþNSCLC (by central immunohistochemistry testing) were random-
ized 1:1 to receive alectinib 600 or crizotinib 250 mg twice-daily until dis-
ease progression, toxicity, withdrawal, or death. Randomization was
stratified by performance status, race, and CNS metastases status.
Patients with treated/untreated asymptomatic brain metastases were
eligible; previous CNS radiotherapy was allowed if completed 14 days
before enrolment. Crossover was not permitted.
ALEX was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice Guidelines. Written
informed consent was obtained from all patients.
End points
CNS efficacy end points [PFS, time to CNS progression, CNS objective
response rate (ORR), and CNS duration of response (DoR)] were ana-
lyzed by subgroup: patients with/without baseline CNS disease and
patients with baseline CNS disease with/without prior radiotherapy.
Assessments
Computed tomography (CT) or magnetic resonance imaging (MRI) of
the chest, abdomen, and brain were carried out at screening. Subsequent
tumor assessment, including systematic brain imaging, was carried out
every 8 weeks until progression, and at the post-treatment visit (4 weeks
after treatment discontinuation). Scans were repeated for suspected
progression.
CNS end points were assessed by an Independent Review Committee
(IRC). Baseline CNS metastases with a minimum size of 10 mm
(CT/MRI scan), 10 mm caliper measurement (clinical examination), or
20 mm (chest X-ray) were considered measurable. Response was assessed
using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exploratory CNS end points (ORR, DoR, and time to CNS progression)
were assessed by Response Assessment in Neuro-Oncology Brain
Metastases (RANO-BM) criteria in patients with baseline CNS
metastases.
Statistical analysis
Comparisons of PFS between treatment groups were based on a
two-sided log-rank test. Kaplan–Meier methods were used to estimate
median PFS with 95% CIs. HRs with 95% CIs were estimated using Cox
proportional-hazards regression. CNS end points assessed by
RANO-BM were analyzed using the same methods as those assessed by
RECIST [13].
Time to CNS progression was analyzed using competing risk method-
ology with minor statistical differences for the cumulative incidence rates
(CIR) of CNS progression and time to CNS progression analysis. These
analyses consider the possibility that at the time of analysis, a patient may
have CNS progression (with/without systemic progression), non-CNS
progression, or death, and include only the first event (see supplementary
Appendix, available at Annals of Oncology online).
Results
Patients
At data cutoff (9 February 2017), 303 patients (alectinib, n¼ 152;
crizotinib, n¼ 151) were randomized; baseline characteristics of
the intent-to-treat (ITT) population have been reported [13].
Forty percent of patients had IRC-assessed baseline CNS meta-
stases (n¼ 122, measurable and/or non-measurable; n¼ 43,
measurable [Figure 1]). Baseline characteristics were generally
balanced between arms (Table 1). A higher proportion of past
and current smokers received alectinib versus crizotinib (36%
and 11% versus 24% and 2%, respectively). Among patients with
measurable and/or non-measurable baseline CNS metastases, 46
had received prior radiotherapy. Patients who received treatment
for CNS progression after study start are described in supplemen-
tary Table S1, available at Annals of Oncology online). The median
number of measurable/non-measurable baseline CNS lesions per
patient was two in both treatment arms (alectinib, range: 1–10;
crizotinib, range: 1–6).
PFS
Investigator-assessed PFS was significantly prolonged with alecti-
nib versus crizotinib in patients with (HR 0.40, 95% CI: 0.25–
0.64) and without baseline CNS metastases (HR 0.51, 95% CI:
0.33–0.80; Figure 2). There was no discernable difference in the
effect of alectinib between patients with/without baseline CNS
metastases (interaction P¼ 0.36). PFS was significantly longer
with alectinib versus crizotinib in patients with (HR 0.34, 95%
CI: 0.15–0.78) and without prior radiotherapy (HR 0.44, 95% CI:
0.25–0.78; Figure 2).
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Time to CNS progression
Time to CNS progression, without prior non-CNS progression,
was significantly longer with alectinib versus crizotinib, and com-
parable between patients with [csHR 0.18 (95% CI: 0.09–0.36)]
and without baseline CNS metastases [csHR 0.14 (95% CI:
0.06–0.33); Table 2] or with [csHR 0.11 (95% CI: 0.03–0.42])
or without prior radiotherapy [csHR 0.22 (95% CI: 0.10–0.50);
supplementary Table S2, available at Annals of Oncology online].
The CIR of CNS progression, without prior non-CNS pro-
gression, was lower over time with alectinib versus crizotinib re-
gardless of baseline CNS metastases or prior radiotherapy
(Figure 3). Twelve-month CIR for CNS progression (without
prior non-CNS progression) were: 58.3% (95% CI: 43.4–70.5)
crizotinib and 16.0% (95% CI: 8.2–26.2) alectinib in patients
with baseline CNS metastases; and 31.5% (95% CI: 22.1–41.3)
crizotinib and 4.6% (95% CI: 1.5–10.6) alectinib in patients
without (Figure 3 and supplementary Table S3, available at
Annals of Oncology online). Twelve-month CIR for non-CNS
progression (without prior CNS progression) were: 24.2%
(95% CI: 13.6–36.5) crizotinib and 12.9% (95% CI: 6.0–22.5)
alectinib in patients with baseline CNS metastases; and 25.3%
(95% CI: 16.7–34.9) crizotinib and 16.7% (95% CI: 9.8–25.2)
alectinib in patients without (supplementary Figure S1 and
Table S3, available at Annals of Oncology online). At primary
analysis, 18 alectinib and 68 crizotinib patients had CNS pro-
gression without prior non-CNS progression; of these, 6 and 8,
respectively, had systemic progression at the time of CNS pro-
gression. CIR for death (without prior progression) for the sub-
groups are shown in supplementary Figure S1 and Table S3,
available at Annals of Oncology online. Similar differences between
12-month CIRs for CNS or non-CNS progression as the first site of
progression between alectinib and crizotinib were seen in patients
with/without prior radiotherapy.
Forty crizotinib-treated patients experienced an isolated
asymptomatic CNS progression per investigator, regardless of
baseline CNS metastases, versus 5 alectinib-treated patients. Of
those, 30/40 patients (75%, crizotinib), and 5/5 patients (100%,
alectinib) received allocated to study treatment after
303 patients randomized (ITT population)
152 assigned to alectinib 151 assigned to crizotinib
58 with measurable and/or
non-measurable
CNS disease at baseline
64 with measurable and/or
non-measurable
CNS disease at baseline
25 had prior brain radiotherapy*
39 had no prior brain radiotherapy
16 WBRT
4 radiosurgery
1 brain surgery combined with radiotherapy
17 WBRT
6 radiosurgery
3 brain surgery combined with radiotherapy
Patients with IRC-assessed baseline
CNS metastases
22 had measurable CNS disease
36 had non-measurable CNS disease
Patients with IRC-assessed baseline
CNS metastases
21 had measurable CNS disease
43 had non-measurable CNS disease
21 had prior brain radiotherapy
37 had no prior brain radiotherapy
Figure 1. Study population overview. *One patient in the alectinib arm received both radiosurgery and whole-brain radiotherapy (WBRT).
CNS, central nervous system; IRC, independent review committee; ITT, intent-to-treat.
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asymptomatic CNS progression. Continuation of study treat-
ment after symptomatic CNS progression was not permitted.
CNS response (RECIST)
CNS ORR in patients with measurable baseline CNS metastases
was 85.7% (n¼ 6/7) alectinib versus 71.4% (n¼ 5/7) crizotinib
in patients with prior radiotherapy, and 78.6% (n¼ 11/14) alecti-
nib versus 40.0% (n¼ 6/15) crizotinib in patients without
(Figure 4). In patients with measurable/non-measurable baseline
CNS metastases, CNS ORR was 36.0% (n¼ 9/25) alectinib versus
28.6% (n¼ 6/21) crizotinib in patients with prior radiotherapy
and 74.4% (n¼ 29/39) alectinib versus 24.3% (n¼ 9/37) crizoti-
nib without prior radiotherapy (Figure 4). Complete response
(CR) rates were higher for alectinib versus crizotinib in patients
with measurable/non-measurable baseline CNS metastases with
prior radiotherapy (61.5% versus 10.8%) and without (20.0%
versus 4.8%; Figure 4).
CNS DoR in patients with measurable/non-measurable base-
line CNS metastases was longer for alectinib versus crizotinib in
patients with prior radiotherapy [median NR (95% CI: 14.8–NR)
versus 11.1 months (95% CI: 13.7–18.1); Figure 4C] and without
[median NR (95% CI: 13.4–NR) versus 3.7 months (95% CI: 2.3–
5.5); Figure 4D]. Data were similar for patients with measurable
baseline CNS metastases.
Efficacy by RANO-BM criteria
Data assessed by RANO-BM criteria were consistent with RECIST-
assessed findings (supplementary Table S4, available at Annals of
Oncology online). In 32 patients with measurable baseline CNS
metastases (alectinib, n¼ 15; crizotinib, n¼ 17), 33% (n¼ 5)
achieved a CNS CR with alectinib versus 0% with crizotinib; 20%
(n¼ 3) achieved a partial response with alectinib versus 29.4%
(n¼ 5) with crizotinib although the sample size was small (supple-
mentary Table S5, available at Annals of Oncology online). Median
CNS DoR in patients with baseline measurable CNS metastases
was 17.3 months with crizotinib and NR with alectinib. CNS ORR
according to prior radiotherapy treatment is shown in supplemen-
tary Table S5, available atAnnals of Oncology online.
Time to CNS progression was significantly longer with alectinib
versus crizotinib in patients with baseline measurable/non-
measurable CNS metastases (csHR 0.23; 95% CI: 0.12–0.48; supple-
mentary Table S6, available at Annals of Oncology online). CIR of
CNS progression in patients with measurable/non-measurable base-
line CNS metastases (supplementary Figure S2, available at Annals of
Oncology online) were consistently lower over time with alectinib ver-
sus crizotinib. Twelve-month CIRs of CNS progression (without
prior non-CNS progression) were 59.4% (95% CI: 43.6–72.1) crizoti-
nib and 19.0% (95% CI: 9.7–30.7) alectinib in patients with
measurable/non-measurable baseline CNS metastases (supplemen-
tary Table S7, available at Annals of Oncology online). The CIR of
non-CNS progression and death in these patients are shown in sup-
plementary Figure S2, available atAnnals of Oncology online.
Discussion
Based on the ALEX data, the National Comprehensive Cancer
Network guidelines were updated to include alectinib as a category
1 recommendation for first-line treatment of ALKþ NSCLC [15].
Our data confirm that alectinib demonstrates superior efficacy ver-
sus crizotinib in treatment-naive advanced ALKþNSCLC, regard-
less of baseline CNS disease or prior radiotherapy.
Baseline CNS metastases are an adverse prognostic factor in
ALKþ advanced NSCLC [16]. Although PROFILE 1014 estab-
lished crizotinib as the SOC first-line therapy for ALKþ NSCLC
[2], only patients with treated and stable CNS disease were
enrolled, and, in contrast to ALEX, regular CNS imaging was only
conducted in patients with known baseline CNS disease [4, 7].
In ASCEND-4 (phase III; first-line ceritinib versus chemotherapy),
32% of patients had asymptomatic or neurologically stable
Table 1. Baseline characteristics in patients with central nervous system
(CNS) disease [Independent Review Committee (IRC)] at baseline
Measurable and/or non-
measurable CNS disease (IRC)
at baseline (n5 122)
Crizotinib
(n558)
Alectinib
(n5 64)
Median age, years (range) 54 (18–81) 58 (25–81)
Gender, n (%)
Male 22 (38) 34 (53)
Female 36 (62) 30 (47)
Ethnicity, n (%)
Asian 28 (48) 27 (42)
Non-Asian 30 (52) 37 (58)
ECOG performance status, n (%)
0–1 53 (91) 59 (92)
2 5 (9) 5 (8)
Smoking history, n (%)
Current smoker 1 (2) 7 (11)
Past smoker 14 (24) 23 (36)
Never smoked 43 (74) 34 (53)
Stage, n (%)a
IIIB 1 (2) 0
IV 57 (98) 64 (100)
Histology, n (%)
Adenocarcinoma 56 (97) 57 (89)
Squamous cell carcinoma 0 2 (3)
Other 2 (3) 3 (5)
Undifferentiated 0 2 (3)
Prior brain radiation, n (%)b
Yes 21 (36) 25 (39)
Whole-brain radiotherapy 16 17
Radiosurgery 4 6
Brain surgery plus radiotherapy 1 3
No 37 (64) 39 (61)
Patients with measurable CNS disease (IRC), n (%)
Yes 22 (38) 21 (33)
No 36 (62) 43 (67)
aDisease stage was assessed by investigators following commonly used
staging systems in local practice.
bOne patient in the alectinib arm received both radiosurgery and
whole-brain radiotherapy.
ECOG, Eastern Cooperative Oncology Group.
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baseline CNS disease [17]. PFS was longer with ceritinib versus
chemotherapy in patients without baseline CNS metastases [HR
0.48 (95% CI: 0.33–0.69), median PFS 26.3 versus 8.3 months]
[17]. Although CNS responses are well documented with ceritinib,
these differences, together with the median PFS of ceritinib in
those with baseline CNS metastases (10.7 months), raise concerns
about the durability of the CNS efficacy of ceritinib. Indeed, the
CNS is a common site of progression in patients treated with crizo-
tinib or ceritinib [17, 18].
ALEX is the first ALK-inhibitor study to include prospective,
standardized assessment of CNS lesions in the ITT population,
regardless of baseline CNS disease, allowing the potential CNS
protective effect of the drug to be assessed. Alectinib significantly
prolonged PFS in patients with/without baseline CNS disease ver-
sus crizotinib, and significantly improved intracranial ORR ver-
sus crizotinib, irrespective of radiotherapy history.
Our data are in agreement with a pooled analysis of alectinib
phase II trials, which demonstrated that CNS efficacy of alectinib is
maintained regardless of radiotherapy history in crizotinib-
pretreated patients [12]. ALEX CNS progression data are consist-
ent with findings from the phase III J-ALEX trial, in which first-
line alectinib reduced the risk of CNS progression versus crizotinib
[19]. However, CNS metastases were not stratified in J-ALEX.
CNS DoR was longer with alectinib versus crizotinib in all ALEX
subgroups. As ALEX only permitted patients with asymptomatic
CNS disease, we do not yet know the potential of alectinib in
improving CNS outcomes in symptomatic patients versus local
CNS therapies. The ALEX data strongly suggest that in asympto-
matic patients, treating CNS metastases with alectinib alone may
result in a reduced or delayed need for local CNS treatment.
Alectinib significantly reduced the risk of CNS progression ver-
sus crizotinib irrespective of the subgroup analyzed, suggesting
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Figure 2. Progression-free survival according to central nervous system (CNS) metastatic status at baseline and history of radiotherapy:
(A) patients with CNS metastases at baseline, (B) patients without CNS metastases at baseline, (C) patients with CNS metastases at baseline
who had received prior radiotherapy, and (D) patients with CNS metastases at baseline who had not received prior radiotherapy. CI, confi-
dence interval; HR, hazard ratio; NR, not reached.
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Figure 3. Cumulative incidence rate (CIR) of central nervous system (CNS) progression. For each patient, the first event of CNS or non-CNS
progression or death was counted: (A) patients with CNS metastases at baseline, (B) patients without CNS metastases at baseline, (C) patients
with CNS metastases at baseline who had received prior radiotherapy, and (D) patients with CNS metastases at baseline who had not
received prior radiotherapy. CI, confidence interval.
Table 2. Risk of central nervous system (CNS) progression, non-CNS progression, and death [Independent review committee (IRC) Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1] in patients with/without baseline CNS metastases
Patients with baseline CNS metastases Crizotinib (n5 58) Alectinib (n564) Cause-specific
HR (95% CI)
P value
(log-rank)Patients with event, n (%) Patients with event, n (%)
CNS progression without prior non-CNS PD 33 (56.9) 12 (18.8) 0.18 (0.09–0.36) <0.0001
Non-CNS progression without prior CNS PD 14 (24.1) 11 (17.2) 0.35 (0.15–0.84) 0.0154
Death without prior CNS or non-CNS PD 4 (6.9) 7 (10.9) 0.66 (0.17–2.55) 0.55
Patients without baseline CNS metastases Crizotinib (n5 93) Alectinib (n588) Cause-specific
HR (95% CI)
P value
(log-rank)Patients with event, n (%) Patients with event, n (%)
CNS progression without prior non-CNS PD 35 (37.6) 6 (6.8) 0.14 (0.06–0.33) <0.0001
Non-CNS progression without prior CNS PD 19 (20.4) 25 (28.4) 1.16 (0.64–2.11) 0.63
Death without prior CNS or non-CNS PD 5 (5.4) 4 (4.5) 0.71 (0.19–2.65) 0.60
For each patient, the first event of CNS progression, systemic progression, or death was counted. Therefore, patients who had CNS progression first were
no longer at risk for a systemic progression or death in this analysis. Patients with CNS progression who also had systemic progression were included in
the CNS progression group. Hazard ratios (HRs) and 95% confidence interval (CI) were estimated by Cox regression where patients with competing events
were censored at the time of these events. P values are from two-sided cause-specific log-rank tests. PD, disease progression.
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that alectinib may have protective effect against development of
CNS metastases. When interpreting the CIR of non-CNS pro-
gression and death, we must consider the methodology used.
Once a patient develops CNS progression, CIR analysis does not
analyze whether subsequent systemic progression occurred ear-
lier with alectinib or crizotinib. As such, some patients were
documented as having CNS progression but may also have
experienced non-CNS progression.
Pooled analysis of phase II studies demonstrated that alectinib
is active against treated/untreated CNS metastases in ALKþ
NSCLC, regardless of assessment criteria (RECIST v1.1 versus
RANO-BM, http://recist.eortc.org/wp-content/uploads/2015/03/
RECISTGuidelines.pdf) [20]. Trends we observed are consistent
with the pooled phase II data, and the ALEX ITT data [13].
Although some subgroups contained small patient numbers, our
findings are consistent with those reported previously [12, 19].
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Figure 4. Central nervous system (CNS) response: (A) patients with measurable CNS disease at baseline who had received prior radiotherapy,
(B) patients with measurable CNS disease at baseline who had not received prior radiotherapy, (C) patients with measurable or non-measur-
able CNS disease at baseline who had received prior radiotherapy, and (D) patients with measurable or non-measurable CNS disease at base-
line who had not received prior radiotherapy. CI, confidence interval; CR, complete response; DoR, duration of response; NR, not reached; RT,
radiotherapy.
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The key strength of our analysis comes from prospective assess-
ment of CNS secondary lesions in the ITT population.
CNS results from ALEX consolidate alectinib as the SOC for
untreated, advanced ALKþ NSCLC irrespective of presence/
absence of baseline CNS metastases.
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